Achillion Pharmaceuticals Inc (NASDAQ:ACHN) major shareholder Qvt Associates Gp Llc sold 128,649 shares of the company’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $7.66, for a total transaction of $985,451.34. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was -6.32% in last session and finished the day at $6.38. Traded volume was 21.04million shares in the last session and the average volume of the stock remained 3.75million shares. The beta of the stock remained 1.89. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) insider ownership is 13.04%.

Questcor Pharmaceuticals Inc (NASDAQ:QCOR) Insider Michael H. Mulroy sold 10,000 shares of the company stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $88.57, for a total value of $885,700.00. Following the completion of the transaction, the insider now directly owns 77,063 shares of the company’s stock, valued at approximately $6,825,470. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) dropped -2.40 percent to $88.81 Thursday on volume of 1.19million shares. The intra-day range of the stock was $88.66 to $90.99. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has a market capitalization of $5.42billion.

Seattle Genetics Inc (NASDAQ:SGEN) CEO Clay B. Siegall sold 11,200 shares of Seattle Genetics stock on the open market in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $40.14, for a total transaction of $449,568.00. Following the transaction, the chief executive officer now directly owns 525,217 shares of the company’s stock, valued at approximately $21,082,210. Seattle Genetics, Inc. (NASDAQ:SGEN)’s stock on June 12, 2014 reported a decrease of -0.05% to the closing price of $40.10. Its fifty two weeks range is $28.15 -$55.99. The total market capitalization recorded $4.94billion. The overall volume in the last trading session was 741,406.00million shares. In its share capital, SGEN has 123.15million outstanding shares.

Repligen Corp. (NASDAQ:RGEN) SVP Daniel P. Witt sold 47,709 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $20.56, for a total transaction of $980,897.04. Following the completion of the sale, the senior vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $205,600. On Thursday, shares of Repligen Corporation (NASDAQ:RGEN) dropped -1.41% to close the day at $19.54. Company return on investment (ROI) is 15.40% and its monthly performance is recorded as 7.66%. Repligen Corporation (NASDAQ:RGEN) quarterly revenue growth is 30.97%.

bluebird bio Inc (NASDAQ:BLUE) COO Jeffrey T. Walsh unloaded 6,000 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $24.23, for a total transaction of $145,380.00. bluebird bio Inc (NASDAQ:BLUE) stock performance was 0.44% in last session and finished the day at $25.27. Traded volume was 87,626.00million shares in the last session and the average volume of the stock remained 235.45K shares. bluebird bio Inc (NASDAQ:BLUE) insider ownership is 1.70%.